证券代码：603351 证券简称：威尔药业 公告编号：2025-004 南京威尔药业集团股份有限公司（以下简称"公司"）近日收到公司控股股东吴仁 荣先生的函告，获悉其所持有的公司部分股份办理了质押，具体情况如下： | | 是否 | 本次质 | 是否 | 是否 | | | | 占其所 | 占公司 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 为控 | | | | 质押 | 质押 | | | | 融资 | | | | 押股数/ | 为限 | 补充 | | | 质权人 | 持股份 | 总股本 | | | 名称 | 股股 | 万股 | 售股 | 质押 | 起始日 | 到期日 | | 比例 | 比例 | 资金 | | | 东 | | | | | | | | | 用途 | | | | | | | | | 南京证 | | | 个人 | | | | | | | | | 券股份 | | | | | 吴仁荣 | 是 | 857 | 否 | 否 | 2025-3-24 | 2026-3-24 | | 46.27% ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [6][7]. Core Insights - The company is advancing in both pharmaceutical excipients and synthetic lubricant base oils, entering a new development phase. The consistent evaluation of generic drugs is accelerating industry upgrades, with high-end pharmaceutical excipients expected to significantly enhance profits. The company has a stable management structure and is well-positioned to benefit from the growing demand for high-quality excipients and lubricants [6][7]. Financial Data and Profit Forecast - Total revenue is projected to grow from 1,156 million yuan in 2023 to 2,071 million yuan in 2026, with a compound annual growth rate (CAGR) of approximately 20.8% [2]. - Net profit attributable to shareholders is expected to increase from 112 million yuan in 2023 to 236 million yuan in 2026, reflecting a CAGR of about 26.9% [2]. - Earnings per share (EPS) is forecasted to rise from 0.83 yuan in 2023 to 1.74 yuan in 2026 [2]. - The gross margin is anticipated to improve from 27.4% in 2023 to 28.8% in 2026 [2]. Market Data - As of February 17, 2025, the closing price of the stock is 24.61 yuan, with a market capitalization of 3,333 million yuan [3]. - The price-to-earnings (PE) ratio is projected to decrease from 30 in 2023 to 14 in 2026, indicating a favorable valuation trend [2][7]. Business Overview - The company specializes in the research and production of pharmaceutical excipients and synthetic lubricant base oils, utilizing core technologies such as ether polymerization and ester synthesis [18]. - The pharmaceutical excipients market in China is still in its early stages, with a market share of less than 5% in the pharmaceutical formulation industry, indicating significant growth potential [6][36]. Product and Application - Key products include the Tween 80 series, polyethylene glycol series, and propylene glycol, which are widely used in various drug formulations [46][50]. - The company is expanding its product line to include high-end injectable excipients, which are expected to drive revenue growth [46][48]. Competitive Landscape - The pharmaceutical excipients market in China is characterized by a fragmented structure, with many small and non-specialized companies. The company is positioned as a significant player among a few established firms [44][45].

证券代码：603351 证券简称：威尔药业 公告编号：2025-003 发证时间：2024 年 11 月 6 日 本次高新技术企业的认定系原证书有效期满后的重新认定。根据《中华人民共 和国企业所得税法》以及国家对高新技术企业的相关税收优惠政策规定，威尔生物 科技自本次通过高新技术企业认定后连续三年（2024年至2026年）可继续享受高新 技术企业的税收优惠政策，即按照 15% 的税率缴纳企业所得税。 南京威尔药业集团股份有限公司董事会 南京威尔药业集团股份有限公司 由于威尔生物科技 2024 年度已根据相关规定按 15% 的税率预缴企业所得税， 故本次获得高新技术企业重新认定不会对 2024 年度经营业绩产生影响。 关于全资子公司获得高新技术企业重新认定的公告 有效期：三年 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司全资子公司南京威尔生物科技有限公司（以下 简称"威尔生物科技"）近日收到由江苏省科学技术厅、江苏省财政厅、国家税务总 局江苏省税务局联合颁发的《高新技术企业证书》，具体信息如 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥312,206,558.92, representing a year-on-year increase of 2.13%[2] - Net profit attributable to shareholders for Q3 2024 was ¥34,002,055.99, up 36.64% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥33,884,294.46, reflecting a 36.69% increase year-on-year[2] - Basic earnings per share for Q3 2024 were ¥0.25, an increase of 31.58% year-on-year[2] - Total operating revenue for Q3 2024 was 128,898,149.74 CNY, an increase from 83,948,045.08 CNY in Q3 2023, representing a growth of approximately 53.5%[14] - Net profit attributable to shareholders of the parent company reached 112,897,296.64 CNY, up from 78,271,460.39 CNY in the same period last year, reflecting a growth of about 44.4%[15] - The total profit for Q3 2024 was 128,731,004.47 CNY, compared to 83,796,714.03 CNY in Q3 2023, representing an increase of approximately 53.5%[14] Cash Flow - The net cash flow from operating activities for Q3 2024 was ¥84,285,195.63, a significant increase of 89.19% compared to the same period last year[2] - The company experienced a significant increase in cash flow due to higher operating revenue, contributing to a year-to-date cash flow increase of 190.11%[5] - Cash flow from operating activities for the first three quarters of 2024 was 161,205,186.32 CNY, significantly higher than 55,567,467.81 CNY in the same period of 2023, marking an increase of about 189%[16] - The company recorded a net cash inflow from operating activities of 842,784,174.82 CNY in the first three quarters of 2024, compared to 617,267,798.70 CNY in the same period of 2023, indicating a growth of about 36.5%[16] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,279,437,409.53, a slight increase of 0.02% from the end of the previous year[3] - Shareholders' equity attributable to the parent company increased by 5.41% year-on-year, reaching ¥1,670,212,016.14[3] - The company's total liabilities amounted to RMB 603,601,125.29, down from RMB 686,221,568.07, indicating a decrease of 12.1%[12] - Short-term borrowings decreased to RMB 331,185,736.11 from RMB 362,221,219.44, a reduction of 8.6%[12] - The retained earnings increased to RMB 528,935,171.78 from RMB 456,669,614.74, representing a growth of 15.8%[12] Research and Development - Research and development expenses for Q3 2024 were 47,691,176.39 CNY, compared to 40,564,145.19 CNY in Q3 2023, indicating an increase of approximately 17.5%[14] Investment Activities - The net cash flow from investing activities was -65,505,220.62, compared to -51,549,090.29 in the previous period, indicating an increase in cash outflow for investments[17] - Cash paid for the acquisition of fixed assets and intangible assets was 43,475,153.98, down from 53,159,960.36, indicating a reduction in capital expenditures[17] - The company reported a cash outflow of 1,400,000.00 related to other investment activities, down from 2,050,000.00, suggesting a decrease in ancillary investment costs[17] Financing Activities - Cash inflow from financing activities totaled 242,886,361.11, down from 365,339,633.34 in the previous period, reflecting a decrease in financing received[17] - Cash outflow for debt repayment was 268,300,000.00, an increase from 241,020,000.00 in the previous period, showing higher debt servicing costs[17] - The net cash flow from financing activities was -84,016,668.97, a significant decline from a positive cash flow of 68,540,370.35 in the previous period, indicating a shift in financing strategy[17] Other Information - The company has not reported any significant changes in major shareholders or their participation in margin trading[10] - There are no new product launches or technological developments mentioned in the report[10]

证券代码：603351 证券简称：威尔药业 公告编号：2024-028 南京威尔药业集团股份有限公司 关于公司2024年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）主营业务为药用辅料及合 成润滑基础油产品的研发、生产和销售。根据上海证券交易所发布的《上市公司行 业信息披露指引第十四号－化工》等文件要求，现将公司 2024 年第三季度主要经营 数据公告如下： | 主要产品 | 2024 年 1-9 月 | | 2024 年 | 1-9 月 | 2024 年 | 1-9 月 | | --- | --- | --- | --- | --- | --- | --- | | | 生产量（吨） | | 销售量（吨） | | 销售收入（万元） | | | 1、合成润滑基础油 | | 45,940.16 | | 44,195.45 | | 69,541.45 | | 其中：机械类 | | 29,608.14 | | 28,904.49 | | 51,622. ...

证券代码：603351 证券简称：威尔药业 公告编号：2024-027 南京威尔药业集团股份有限公司 关于高管集中竞价减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 高管持股的基本情况： 公司于 2024 年 5 月 22 日披露了关于高管集中竞价减持股份计划的相关公告， 公司高管邹建国先生直接持有公司股票 37,500 股，约占公司总股本的 0.0277%， 通过公司 2021 年限制性股票激励计划授予取得； 拟自公告披露之日起十五个交 易日后 3 个月内通过集中竞价交易方式，合计减持公司股份不超过 9,300 股。 集中竞价减持计划的实施结果情况： 截至 2024 年 9 月 11 日，本次减持计划时间届满，邹建国先生已通过集中竞 价交易方式减持股份 9,300 股，目前直接持有公司股份 28,200 股，约占公司总 股本的 0.0208%。 一、集中竞价减持主体减持前基本情况 | 股东名称 | 股东身份 | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | ...

Summary of Conference Call Company/Industry Involved - The document does not specify a particular company or industry involved in the conference call Core Points and Arguments - The content of the conference call is strictly confidential and intended for internal reference only, prohibiting any form of disclosure or external sharing of the information discussed [1] Other Important but Possibly Overlooked Content - Any unauthorized disclosure or distribution of the conference call minutes is considered an infringement, and the organizing entity reserves the right to pursue legal action against violators [1]

证券代码：603351 证券简称：威尔药业 公告编号：2024-024 南京威尔药业集团股份有限公司 （二）主要原材料价格波动情况 关于公司2024年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）主营业务为药用辅料及合 成润滑基础油产品的研发、生产和销售。根据上海证券交易所发布的《上市公司行 业信息披露指引第十四号－化工》等文件要求，现将公司 2024 年半年度主要经营数 据公告如下： | 主要产品 | 年 2024 1-6 | 月 | 年 2024 | 月 1-6 | 年 2024 | 月 1-6 | | --- | --- | --- | --- | --- | --- | --- | | | 生产量（吨） | | | 销售量（吨） | | 销售收入（万元） | | 1、合成润滑基础油 | | 32,532.38 | | 30,100.64 | | 48,137.35 | | 其中：机械类 | | 21,526.41 | | 20,196.6 ...

一、监事会会议召开情况 南京威尔药业集团股份有限公司 第三届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）第三届监事会第九次会议 于 2024 年 8 月 16 日在公司会议室以现场结合通讯方式召开。本次会议通知已于 2024 年 8 月 6 日以书面方式发出。会议由监事会主席吴荣文先生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开程序符合《公司法》及《公司章程》 等相关规定，会议合法有效。 二、监事会会议审议情况 （一）审议通过了《关于 2021 年限制性股票激励计划第三个解除限售期解除限 售条件成就的议案》 经核查，监事会认为：根据《上市公司股权激励管理办法》《公司 2021 年限制 性股票激励计划》及《公司 2021 年限制性股票激励计划实施考核管理办法》等相关 规定，公司 2021 年限制性股票激励计划第三个解除限售期解除限售条件已经成就， 49 名激励对象符合第三个解除限售期解除限售条件，其作为本次可解除限售的激励 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥688,157,870.31, representing a 31.59% increase compared to ¥522,970,497.42 in the same period last year[11]. - The net profit attributable to shareholders for the first half of 2024 was ¥78,895,240.65, a 47.78% increase from ¥53,386,352.50 in the previous year[11]. - The net cash flow from operating activities surged to ¥76,919,990.69, marking a significant increase of 598.26% compared to ¥11,015,972.51 in the same period last year[11]. - Basic earnings per share for the first half of 2024 were ¥0.58, up 48.72% from ¥0.39 in the same period last year[12]. - The company reported a net profit excluding non-recurring gains and losses of ¥69,388,207.45, which is a 30.93% increase from ¥52,997,229.42 in the same period last year[11]. - The company reported a significant market risk in the pharmaceutical excipients industry, indicating that companies with low product quality and outdated technology will gradually lose market share, while those with high-quality standards and strong R&D capabilities will expand rapidly[31]. - The company highlighted the potential for the pharmaceutical excipients market to grow, driven by the implementation of consistency evaluation policies for generic drugs, which will raise industry barriers and entry thresholds[31]. Revenue and Sales Growth - The company's operating revenue increased by 31.59% due to higher sales volume during the reporting period[13]. - Net profit attributable to shareholders increased by 47.78%, primarily driven by the rise in operating revenue[13]. - Basic earnings per share rose by 48.72% as a result of the increase in net profit[13]. - Sales volume of synthetic lubricating base oil increased by 32.77%, with sales revenue rising by 34.40%[22]. - Sales volume of pharmaceutical excipients grew by 30.34%, while sales revenue increased by 23.14%[22]. Assets and Liabilities - The total assets as of June 30, 2024, amounted to ¥2,345,378,363.95, reflecting a 2.92% increase from ¥2,278,902,659.40 at the end of the previous year[11]. - The net assets attributable to shareholders increased to ¥1,624,746,926.84, a 2.55% rise from ¥1,584,423,033.38 at the end of the previous year[11]. - Accounts receivable increased by 28.39% compared to the end of the previous year, mainly due to higher sales volume during the reporting period[26]. - Other receivables decreased by 47.23% compared to the end of the previous year, primarily due to the receipt of export tax rebates from the State Administration of Taxation[26]. - Non-current liabilities due within one year increased by 129.50% compared to the end of the previous year, mainly due to the reclassification of certain long-term borrowings[27]. Research and Development - R&D expenses amounted to CNY 31.83 million, a year-on-year increase of 25.30%, representing 4.63% of operating revenue[23]. - The company has 49 ongoing research projects, including 4 raw material drug projects and 9 newly initiated projects[23]. - The company aims to enhance its competitive edge in the pharmaceutical excipient sector through ongoing investment projects[20]. Environmental Compliance - The company’s subsidiary, Weier Biotechnology, is classified as a key pollutant discharge unit but reported no exceedance of pollutant discharge limits during the reporting period[38]. - The company’s subsidiary, Weier Pharmaceutical Technology, also reported no exceedance of pollutant discharge limits and properly disposed of hazardous waste through qualified third parties[38]. - The company has passed the ISO14001 environmental management system certification, establishing effective environmental management practices[45]. - No administrative penalties were imposed on the company during the reporting period due to environmental issues[45]. Shareholder and Governance - The company has not disclosed any plans for profit distribution or capital reserve conversion during this reporting period[2]. - The company has not reported any changes in its board of directors, supervisors, or senior management during the reporting period[34]. - The company has committed to not transferring or managing shares for 36 months post-IPO, with specific conditions for extending the lock-up period[48]. - Major shareholders commit to not reducing their holdings within 2 years after the lock-up period, with a maximum reduction of 25% of their holdings per year[51]. Financial Reporting and Accounting Policies - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance and relevant regulations, ensuring a true, accurate, and complete reflection of the company's financial status and operating results[105]. - The company adheres to a 12-month operating cycle for liquidity classification of assets and liabilities[107]. - The company’s accounting policies include revenue recognition and measurement, inventory measurement, and fixed asset depreciation methods[104]. - The company recognizes revenue when control of goods or services is transferred to the customer, either at a point in time or over a period of time, depending on the fulfillment obligations[172]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[78]. - The company is actively developing new lubricant products to address competitive pressures in the lubricant industry, which may be affected by global economic downturns and domestic demand declines[31]. - The company aims to complete the transition of certain products to Nanjing Reagents by December 31, 2024, to eliminate overlap in production[58].